Lysine Acetylation Inhibits α-Synuclein Fibrillation

  • WU Qiong ,
  • LI Cong-gang ,
  • ZHAI Zi-ning
Expand
  • 1. Key Laboratory of Magnetic Resonance in Biological Systems, State Key Laboratory of Magnetic Resonance and Atomic and Molecular Physics, National Center for Magnetic Resonance in Wuhan(Wuhan Institute of Physics and Mathematics, Chinese Academy of Sciences), Wuhan 430071, China;
    2. University of Chinese Academy of Sciences, Beijing 100049, China

Received date: 2015-05-13

  Revised date: 2016-04-18

  Online published: 2016-06-05

Supported by

Ministry of Science and Technology of China (2013CB910200);National Natural Science Foundation of China (21173258, 21120102038 and 21221064).

Abstract

Fibrils of intrinsically disordered protein α-synuclein (α-syn) are hallmarks of Parkinson's disease. Electrostatic interactions are known to contribute significantly on α-syn aggregation. Here we studied how α-syn conformation and fibrillation were affected by changing the net charge of the protein via acetylation of lysine side chains. NMR spectroscopy results showed that lysine-acetylated α-syn remained disordered, and showed a more extended conformation, relative to wild-type protein. Acetylation inhibited α-syn fibrillation, revealed by thioflavin (ThT) fluorescence assay. The N- and C-terminals of the acetylated protein were highly negative charged, causing increased exposure of the non-amyloid-β component (NAC) region. It is proposed that, with the charge distribution in the acetylated protein, electrostatic repulsion, instead of hydrophobic effect, may contribute predominately to the aggregation. This charge-effect mechanism may constitute a new strategy to inhibit α-syn fibrillation.

Cite this article

WU Qiong , LI Cong-gang , ZHAI Zi-ning . Lysine Acetylation Inhibits α-Synuclein Fibrillation[J]. Chinese Journal of Magnetic Resonance, 2016 , 33(2) : 179 -187 . DOI: 10.11938/cjmr20160201

References

[1] Goedert M. Alpha-synuclein and neurodegenerative diseases[J]. Nat Rev Neurosci, 2001, 2(7):492-501.

[2] Trojanowski J Q, Lee V M Y. Parkinson's disease and related alpha-synucleinopathies are brain amyloidoses[J]. Ann NY Acad Sci, 2003, 991:107-110.

[3] Spillantini M G, Crowther R A, Jakes R, et al. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies[J]. Proc Natl Acad Sci U S A, 1998, 95(11):6469-6473.

[4] Ulmer T S, Bax A, Cole N B, et al. Structure and dynamics of micelle-bound human alpha-synuclein[J]. J Biol Chem, 2005, 280(10):9595-9603.

[5] Bussell R J, Eliezer D. A structural and functional role for 11-mer repeats in alpha-synuclein and other exchangeable lipid binding proteins[J]. J Mol Biol, 2003, 329(4):763-778.

[6] El-Agnaf O M A, Bodles A M, Guthrie D J S, et al. The N-terminal region of non-A beta component of Alzheimer's Disease amyloid is responsible for its tendency to assume beta-sheet and aggregate to form fibrils[J]. Eur J Biochem, 1998, 258(1):157-163.

[7] Murray I V J, Giasson B I, Quinn S M, et al. Role of alpha-synuclein carboxy-terminus on fibril formation in vitro[J]. Biochemistry, 2003, 42(28):8530-8540.

[8] Uversky V N. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation[J]. J Neurochem, 2007, 103(1):17-37.

[9] Wood S J, Wypych J, Steavenson S, et al. Alpha-synuclein fibrillogenesis is nucleation-dependent:Implications for the pathogenesis of Parkinson's disease[J]. J Biol Chem, 1999, 274(28):19509-19512.

[10] Uversky V N, Li J, Fink A L. Evidence for a partially folded intermediate in alpha-synuclein fibril formation[J]. J Biol Chem, 2001, 276:10737-10744.

[11] Fernandez C O, Hoyer W, Zweckstetter M, et al. NMR of alpha-synuclein-polyamine complexes elucidates the mechanism and kinetics of induced aggregation[J]. Embo J, 2004, 23(10):2039-2046.

[12] Bertoncini C W, Jung Y S, Fernandez C O, et al. Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein[J]. Proc Natl Acad Sci U S A, 2005, 102(5):1430-1435.

[13] Sung Y H, Eliezer D. Residual structure, backbone dynamics, and interactions within the synuclein family[J]. J Mol Biol, 2007, 372(3):689-707.

[14] Dedmon M M, Lindorff-Larsen K, Christodoulou J, et al. Mapping long-range interactions in alpha-synuclein using spin-label NMR and ensemble molecular dynamics simulations[J]. J Am Chem Soc, 2005, 127(2):476-477.

[15] Hoyer W, Cherny D, Subramaniam V, et al. Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro[J]. Biochemistry, 2004, 43(51):16233-16242.

[16] Wu K P, Weinstock D S, Narayanan C, et al. Structural reorganization of alpha-synuclein at low pH observed by NMR and REMD simulations[J]. J Mol Biol, 2009, 391(4):784-796.

[17] Arnesen T, Van Damme P, Polevoda B, et al. Proteomics analyses reveal the evolutionary conservation and divergence of N-terminal acetyltransferases from yeast and humans[J]. Proc Natl Acad Sci U S A, 2009, 106(20):8157-8162.

[18] Hoyer W, Antony T, Cherny D, et al. Dependence of alpha-synuclein aggregate morphology on solution conditions[J]. J Mol Biol, 2002, 322(2):383-393.

[19] Shaw B F, Arthanari H, Narovlyansky M, et al. Neutralizing positive charges at the surface of a protein lowers its rate of amide hydrogen exchange without altering its structure or increasing its thermostability[J]. J Am Chem Soc, 2010, 132(49):17411-17425.

[20] Ferrage F, Zoonens M, Warschawski D E, et al. Slow diffusion of macromolecular assemblies by a new pulsed field gradient NMR method[J]. J Am Chem Soc, 2003, 125(9):2541-2545.

[21] Khurana R, Coleman C, Ionescu-Zanetti C, et al. Mechanism of thioflavin T binding to amyloid fibrils[J]. J Struct Biol, 2005, 151(3):229-238.

[22] Fink A L. The aggregation and fibrillation of alpha-synuclein[J]. Acc Chem Res, 2006, 39(9):628-634.

Outlines

/